Sanofi takes over Bioverativ in US$11.8...Seven years after the acquisition of Genzyme, French drug major Sanofi has added another orphan drug player to its portfolio. The company agreed with the management of US blood disorder expert Bioverativ … more ➔
Novel blood test detects eight cancersItalian, US and Australian researchers have used a blood screening test to detect cancer in patients with 8 different cancers whose tumors had not yet spread. Its sensivity is among the best performances … more ➔
Government funds TxCell’s CAR-Treg...French immunotherapy company TxCell received a €1.2m funding from the French governemt agency Bpifrance to develop its genetically engineered regulatory T cells (Tregs). more ➔
Da Volterra’s DAV132 helps fightin...French microbiota specialist Da Volterra announced that its colon-targeted adsorbent, DAV132, can protect the intestinal microbiota from disruption caused by antibiotics. more ➔
Avacta Group plc partners with GlytheraAntibody Drug Conjugate (ADC) specialist Glythera has licensed Actava Group’s Affimer technology in order to develop drug conjugates using the combined technologies. Affimers are small, stable … more ➔
European biotech stocks: 2017 with stron...In 2017, the stock market was a strong financial resource for the European biotech sector – with a significant volume increase in IPOs and follow-on financings compared to 2016. This says the most recent … more ➔
Western diet triggers inflammatory disea...Immunologists headed by Eicke Latz (Univ. of Bonn, Germany) have found out that calorie-rich, fatty Western diet reprogrammes the innate immune system to become hyperreactive to inflammatory triggers. … more ➔
Scientists crack down immune cells that...So far, there is no cure to stop fibrosis, the pathogenic proliferation of connective tissue of the skin and in organs, in autoimmune diseases such as systemic sclerosis (scleroderma). An US-Italian … more ➔
Truffle Capital closes new BioMedTech ve...French venture capitalist Truffle Capital announced the first closing of its BioMedTech venture fund aimed at investments into North American and European medical devices and biotechnology start-ups … more ➔
Ablynx rejects Novo’s €2.3bn bidNanobody developer Ablynx NV has stated that the take-over cash price of €28 per share + optional €2.50 per share as Contingent Value Right (CVR) offered by Novo Nordisk A/S at the end of December … more ➔
